Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Mar;62(3):367-374.
doi: 10.1007/s00592-024-02361-7. Epub 2024 Sep 5.

IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study

Maria Elena Malighetti  1 , Laura Molteni  2 , Emanuela Orsi  3 , Roberta Serra  4 , Alessia Gaglio  3 , Federica Mazzoleni  5 , Filomena Russo  6 , Antonio Carlo Bossi  5
Affiliations
Observational Study

IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study

Maria Elena Malighetti et al. Acta Diabetol. 2025 Mar.

Abstract

Aims: To assess the effects of IDegLira on glucometric indices deriving from intermittently scanned Continuous Glucose Monitoring (isCGM) in patients with type 2 diabetes (T2D).

Methods: Retrospective, observational, cohort, multi-center, "pre - post" study. All adults consecutively identified in the medical records who started treatment with IDegLira, and for whom an isCGM report before and after the initiation of IDegLira was available were included in the study. Time in range (TIR) represented the primary endpoint. Additional glucometric indices, insulin doses and body weight were also assessed.

Results: Overall, 87 patients were included by 5 diabetes centers [mean age 70.2 ± 11.0 years, mean duration of T2D 15.5 ± 9.6 years; BMI 29.4 ± 5.4 kg/m2, baseline HbA1c 9.1 ± 2.1%, 33% insulin naïve, 20.7% treated with basal-oral therapy (BOT), and 46% treated with multiple daily injections of insulin (MDI)]. After an average of 1.7 weeks from IDegLira initiation, TIR significantly increased from 56.8 ± 23.5% to 81.3 ± 13.5% (p < 0.0001), TAR decreased from 42.3 ± 24.2% to 17.1 ± 13.6% (p < 0.0001), while TBR remained steadily low (from 1.3 ± 2.3% to 1.4 ± 2.6%; p = 0.62). Estimated HbA1c decreased from 9.1 ± 2.1% to 6.7 ± 0.6% (p < 0.0001) and percentage of patients with a blood glucose coefficient of variation ≥ 36% dropped from 33.2 to 13.8% (p = 0.0005). In patients on MDI, the reduction in the total insulin dose was substantial (from 55.8 ± 31.2 IU to 27.2 ± 12.3 U).

Conclusions: In T2D patients with poor metabolic control, either insulin naïve or treated with BOT or MDI, the introduction of IDegLira produces a significant increase in the time spent in good metabolic control and a marked reduction in glycemic fluctuations.

Keywords: Glucometric indices; Glucose variability; IDegLira; Time in range; Type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. The study protocol was approved by the Territorial Ethics Committee Lombardia 3, Italy (Prot. No. 278 – date January 3, 2024). Informed consent was obtained from all patients for being included in the study. Conflict of interest: No conflict of interest. Medical writing and/or editorial assistance: Editorial assistance provided by CORESEARCH SRL (Maria Chiara Rossi, Giusi Graziano) and the Open Access fee was funded through a Novo Nordisk S.p.A. unconditional grant. The authors of the publication are fully responsible for the contents and conclusions. Novo Nordisk S.p.A. did not influence and has not been involved in the data interpretation presented in the manuscript.

References

    1. American Diabetes Association Professional Practice Committee (2024) 9. Pharmacologic approaches to Glycemic Treatment: standards of Care in Diabetes-2024. Diabetes Care 47:S158–S178 - DOI - PMC - PubMed
    1. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM (2012) Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med 29:682–689 - DOI - PMC - PubMed
    1. Little S, Shaw J, Home P (2011) Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther 13:S53–64 - DOI - PubMed
    1. George D, Karim A, Florence M (2010) Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Diabetes Technol Ther 12:1019–1027 - DOI - PMC - PubMed
    1. Dale J, Martin S, Gadsby R (2010) Insulin initiation in primary care for patients with type 2 diabetes: 3-year follow-up study. Prim Care Diabetes 4:85–89 - DOI - PubMed

Publication types

LinkOut - more resources